middle.news
FDA Signals Support for Mesoblast’s Rexlemestrocel-L in Chronic Back Pain and Opioid Reduction
10:32am on Monday 19th of January, 2026 AEDT
•
Healthcare
Read Story
FDA Signals Support for Mesoblast’s Rexlemestrocel-L in Chronic Back Pain and Opioid Reduction
10:32am on Monday 19th of January, 2026 AEDT
Key Points
FDA acknowledges clinically meaningful 12-month pain reduction with rexlemestrocel-L
Potential opioid reduction benefits may be included in product labelling
Second Phase 3 trial (MSB-DR004) over 50% enrolled, targeting 300 patients
Rexlemestrocel-L holds Regenerative Medicine Advanced Therapy (RMAT) designation
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE